erlotinib hydrochloride has been researched along with tetraphenylporphine in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (tetraphenylporphine) | Trials (tetraphenylporphine) | Recent Studies (post-2010) (tetraphenylporphine) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 281 | 1 | 133 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berg, K; Selbo, PK; Weyergang, A | 1 |
1 other study(ies) available for erlotinib hydrochloride and tetraphenylporphine
| Article | Year |
|---|---|
Sustained ERK [corrected] inhibition by EGFR targeting therapies is a predictive factor for synergistic cytotoxicity with PDT as neoadjuvant therapy.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Count; Cell Line, Tumor; Cell Survival; Cetuximab; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation; Humans; Molecular Targeted Therapy; Neoadjuvant Therapy; Photochemotherapy; Photosensitizing Agents; Porphyrins; Quinazolines; Signal Transduction; Tyrphostins | 2013 |